Latest On Endo International plc (ENDP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-08-20 00:01 EST | News | Endo: End Game And What Burned Investors Can Learn | N/A |  |
| 2022-08-17 00:23 EST | News | Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg | N/A | |
| 2022-08-17 00:23 EST | News | Endo files for Chapter 11 bankruptcy; in restructuring support agreement with creditors | N/A | |
| 2022-08-09 23:37 EST | News | Endo Non-GAAP EPS of -$0.03 beats by $0.11, revenue of $569.11M beats by $44.54M | N/A | |
| 2022-08-09 23:37 EST | News | Endo epilepsy therapy cenobamate gets Health Canada review | N/A | |
About Endo International plc (ENDP):
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urolog read more...y. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
General
- Name Endo International plc
- Symbol ENDP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 3,397
- Fiscal Year EndDecember
- IPO Date1996-09-25
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.endo.com
Valuation
- Trailing PE 10.29
- Forward PE 3.92
- Price/Sales (Trailing 12 Mt.) 0.67
- Enterprise Value Revenue 3.12
- Enterprise Value EBITDA 8.81
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $2.11
- Next Year EPS Estimate $2.12
- Next Quarter EPS Estimate $0.53
- Profit Margin 6%
- Operating Margin 24%
- Return on Assets 5%
- Revenue 2.9 billion
- Earnings Per Share $0.79
- Revenue Per Share $12.66
- Gross Profit 1.52 billion
- Quarterly Earnings Growth -0.6%
Highlights
- Market Capitalization 1.87 billion
- EBITDA 790.81 million
- PEG Ratio -0.13
- Analyst Target Price $7.7
- Book Value Per Share -$2.61
Share Statistics
- Shares Outstanding 230.5 million
- Shares Float 190.42 million
- % Held by Insiders 116%
- % Held by Institutions 82.44%
- Shares Short 19.69 million
- Shares Short Prior Month 19.62 million
- Short Ratio 4.85
- Short % of Float 12%
- Short % of Shares Outstanding 9%
Technicals
- Beta 1.39
- 52 Week High $10.73
- 52 Week Low $2.71
- 50 Day Moving Average 8.56
- 200 Day Moving Average 5.96
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Endo International plc (ENDP) Dividend Calendar:
Endo International plc (ENDP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Endo International plc (ENDP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Endo International plc (ENDP) Chart:
Endo International plc (ENDP) News:
Below you will find a list of latest news for Endo International plc (ENDP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Endo International plc (ENDP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ENDP Trades:
Endo International plc (ENDP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | SC TO-T/A (Tender offer statement by Third Party) | |
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-02 | SC TO-T (Tender offer statement by Third Party) | |
| 2020-10-29 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-29 | SC 13D (General statement of acquisition of beneficial ownership) | |
| 2020-10-19 | 8-K (Current report) | |
| 2020-10-19 | SC TO-C (Written communication relating to an issuer or third party) | |
| 2020-10-19 | SC TO-C (Written communication relating to an issuer or third party) | |
| 2020-09-24 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-09-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-26 | 8-K (Current report) | |
| 2020-08-17 | 8-K (Current report) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
Endo International plc (ENDP) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Endo International plc (ENDP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 116%
Institutional Ownership: 8244%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-07-29 | Mary Christine Smith | Director | Buy | 21,747.00 | 21,747.00 | | ||
| 2020-06-12 | Nancy J Hutson | Director | Buy | 25,511.00 | 103,464.00 | | ||
| 2020-06-12 | Shane Cooke | Director | Buy | 25,511.00 | 107,585.00 | | ||
| 2020-06-12 | WILLIAM P MONTAGUE | Director | Buy | 25,511.00 | 118,382.00 | | ||
| 2020-06-12 | ROGER H KIMMEL | Director | Buy | 25,511.00 | 148,820.00 | | ||
| 2020-06-12 | Mark G Barberio | Director | Buy | 25,511.00 | 25,511.00 | | ||
| 2020-06-12 | MICHAEL HYATT | Director | Buy | 25,511.00 | 332,509.00 | | ||
| 2020-02-25 | Matthew Joseph Maletta | EVP, Chief Legal Officer | Sell | 32,221.00 | 140,490.00 | | ||
| 2020-02-25 | Blaise Coleman | EVP, Chief Financial Officer | Sell | 33,169.00 | 144,226.00 | | ||
| 2020-02-25 | Matthew Joseph Maletta | EVP, Chief Legal Officer | Buy | 29,527.00 | 145,085.00 | | ||
| 2020-02-25 | Blaise Coleman | EVP, Chief Financial Officer | Buy | 30,395.00 | 148,724.00 | | ||
| 2020-02-25 | Terrance J Coughlin | EVP, Chief Operating Officer | Sell | 56,861.00 | 180,394.00 | | ||
| 2020-02-25 | Jack D. Boyle | SVP, Controller | Sell | 4,376.00 | 20,417.00 | | ||
| 2020-02-25 | Jack D. Boyle | SVP, Controller | Buy | 4,009.00 | 21,517.00 | | ||
| 2020-02-25 | Terrance J Coughlin | EVP, Chief Operating Officer | Buy | 52,107.00 | 308,574.00 | | ||
| 2020-02-25 | Rahul Garella | EVP, Intl Pharmaceuticals | Buy | 9,726.00 | 40,285.00 | | ||
| 2020-02-25 | Rahul Garella | EVP, Intl Pharmaceuticals | Sell | 10,614.00 | 46,752.00 | | ||
| 2020-02-25 | Patrick A Barry | EVP & Chief Commercial Officer | Buy | 13,199.00 | 64,960.00 | | ||
| 2020-02-25 | Patrick A Barry | EVP & Chief Commercial Officer | Sell | 14,404.00 | 66,150.00 | | ||
| 2020-02-25 | Paul Campanelli | President, CEO | Sell | 227,445.00 | 845,143.00 | |